<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136289">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02056080</url>
  </required_header>
  <id_info>
    <org_study_id>MED-DBL-2012-01</org_study_id>
    <nct_id>NCT02056080</nct_id>
  </id_info>
  <brief_title>Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib</brief_title>
  <acronym>TRASTYVERE</acronym>
  <official_title>Observational, Retrospective and Multicenter Study to Evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medica Scientia Innovation Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medica Scientia Innovation Research</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective, observational, not EPA, multicenter study to evaluate the Clinical Benefit
      of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive
      Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib between January
      2005 and December 2011
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Clinical response rate assessed by RECIST criteria</measure>
    <time_frame>Up to 24 weeks from the first clinical response rate assessment</time_frame>
    <safety_issue>No</safety_issue>
    <description>clinical benefit rate (CBR): defined as the percentage of patients who achieved an objective response (CR or PR) or tumor stabilization for at least 24 weeks or more during the period of treatment with the combination TL.
This variable will be assessed by RECIST v 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the progression-free survival in patients treated TL combination , previously treated with trastuzumab and / or lapatinib</measure>
    <time_frame>Up to one year from the last dose of TL</time_frame>
    <safety_issue>No</safety_issue>
    <description>The progression will be evaluated by RECIST v 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the clinical benefit and time to intra-patient progression between the combination TL and previous treatment lines.</measure>
    <time_frame>Up to 24 weeks from the last dose of TL</time_frame>
    <safety_issue>No</safety_issue>
    <description>clinical benefit: defined as reaching a (complete or partial) objective response or stabilization of tumor for more than 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the time to progression of different subpopulations according to the biological characteristics of the tumor.</measure>
    <time_frame>Up to one year from the last dose of TL</time_frame>
    <safety_issue>No</safety_issue>
    <description>The progression will be evaluated by RECIST v 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify the toxicity profile of the combination TL as a factor related to the intra-patient clinical benefit</measure>
    <time_frame>Up to one year from the last dose of TL</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse reactions observed during treatment of the combination TL, measured with scale CTCAE v.4</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Breast Neoplasm</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HER2 positive metastatic breast cancer who progressed to antiHER2 therapy
        with trastuzumab and / or lapatinib for the metastasic disease and that between January
        2005 and December 2011, began treatment with the combination of trastuzumab and lapatinib
        (TL).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of metastatic breast cancer HER2-positive phenotype (confirmed by
             IHC 3 + or FISH positive)

          -  Older than 18 years

          -  Progressed to at least one prior treatment line for MBC with trastuzumab and / or
             lapatinib, either as monotherapy or in combination with chemotherapy or hormonal
             therapy schemes

          -  Having the patient's complete medical history that contains all lines antiHER2
             therapy treatment

          -  Being a patient who initiated the combination of trastuzumab and lapatinib between
             January 2005 and December 2011

          -  Inform the patient and get the signature of the informed consent

        Exclusion Criteria:

          -  Not having phenotypic classification of the tumor by IHC or FISH test for HER2

          -  Being a patient with HER2-negative phenotype(FISH negative or IHC in range [0-2 +]
             without FISH)

          -  Being a patient who received the trastuzumab and/or lapatinib treatment  (TL) in
             combination with chemotherapy

          -  Being a patient who, since January 2012, began TL therapy for metastatic disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquin Gávila, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Valencia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Duna Zaragoza</last_name>
    <email>duna.zaragoza@medsir.org</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaen</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Navarra</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Neoplasm</keyword>
  <keyword>Receptor,HER2</keyword>
  <keyword>Antineoplastic agent</keyword>
  <keyword>Antibodies, monoclonal</keyword>
  <keyword>Trastuzumab, Lapatinib</keyword>
  <keyword>Protein kinase inhibitors</keyword>
  <keyword>quinazolines</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
    <mesh_term>Protein Kinase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
